C and CX3C chemokines: Cell sources and physiopathological implications

Critical Reviews in Immunology

Volumn 24, Issue 3, 2004, Pages 205-228

  Stievano, Laura ^a   Piovan, Erich ^a   Amadori, Alberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chemokines; CX3CL1; Inflammation; Leukocytes; Tumor immunology; XCL1

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CX3C CHEMOKINE; FRACTALKINE; LYMPHOTACTIN; CX3CR1 PROTEIN, HUMAN; CX3CR1 PROTEIN, MOUSE; GAMMA CHEMOKINE; MEMBRANE PROTEIN; XCL1 PROTEIN, HUMAN; XCL1 PROTEIN, MOUSE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; CROHN DISEASE; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; LUNG GRANULOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ANIMAL; ARTERIOSCLEROSIS; BIOLOGICAL MODEL; CHEMISTRY; GENE EXPRESSION; GENETICS; GRANULOMA; IMMUNOLOGY; LUNG; NEOPLASM; PHYSIOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ARTERIOSCLEROSIS; ARTHRITIS, RHEUMATOID; CHEMOKINES, C; CHEMOKINES, CX3C; CROHN DISEASE; GENE EXPRESSION; GLOMERULONEPHRITIS, IGA; GRAFT REJECTION; GRANULOMA; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 7044227965     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v24.i3.40     Document Type: Review

References (181)

1. Kennedy J, Vicari AP, Saylor V, Zurawski SM, Copeland NG, Gilbert DJ, Jenkins NA, Zlotnik A. A molecular analysis of NKT cells: identification of a class-I restricted T cell-associated molecule (CRTAM). J Leukoc Biol 2000; 67:725-734.
2. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2:123-128.
3. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2:108-115.
4. Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001; 2001:1-18.
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-568.
6. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385:640-644.
7. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387:611-617.
8. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schau TJ, Zlotnik A. XCL1: a cytokine that represents a new class of chemokine. Science 1994; 266:1395-1399.
9. Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, Schneider PV, Cocks BG, Bacon KB, Zlotnik A. Molecular cloning and functional characterization of human XCL1. J Immunol 1995; 155:203-209.
10. Yoshida T, Imai T, Kakizaki M, Nishimura M, Yoshie O. Molecular cloning of a novel C or gamma type chemokine, SCM-1. FEBS Lett 1995; 360:155-159.
11. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4:155-160.
12. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270:27348-27357.
13. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002; 82:1311-1329.
14. Rollins BJ. Chemokines. Blood 1997; 90:909-928.
15. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989; 244:487-493.
16. Kelner GS, Zlotnik A. Cytokine production profile of early thymocytes and the characterization of a new class of chemokine. J Leukoc Biol 1995; 57:778-781.
17. Hedrick JA, Zlotnik A. XCL1. Clin Immunol Immunopathol 1998; 87:218-222.
18. Kuloglu ES, McCaslin DR, Markley JL, Volkman BF. Structural rearrangement of human XCL1, a C chemokine, under physiological solution conditions. J Biol Chem 2002; 277:17863-17870.
19. Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T, Yoshie O. Structure and expression of two highly related genes encoding SCM-1/human XCL1. FEBS Lett 1996: 395:82-88.
20. Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T, Zlotnik A. XCL1 is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 1997; 158:1533-1540.
21. Hedrick JA, Zlotnik A. Chemokines and lymphocyte biology. Curr Opin Immunol 1996; 8:343-347.
22. Allavena P, Bianchi G, Giardina P, Polentarutti N, Zhou D, Introna M, Sozzani S, Mantovani A. Migratory response of human NK cells to monocyte-chemotactic proteins. Methods 1996; 10:145-149.
23. Vissers JL, Hartgers FC., Lindhout E, Teunissen MB, Figdor CG, Adema GJ. Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J Leukoc Biol 2001; 69:785-793.
24. Rumsaeng V, Vliagoftis H, Oh CK, Metcalfe DD. XCL1 gene expression in mast cells following Fc(epsilon) receptor I aggregation: modulation by TGF-beta, IL-4, dexamethasone, and cyclosporin A. J Immunol 1997; 158:1353-1360.
25. Boismenu R, Feng L, Xia YY, Chang JC, Havran WL. Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J Immunol 1996; 157:985-992.
26. Cipriani B, Borsellino G, Poccia F, Placido R, Tramonti D, Bach S, Battistini L, Brosnan CF. Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 2000; 95:39-47.
27. Tikhonov I, Kitabwalla M, Wallace M, Malkovsky M, Volkman B, Pauza CD. Staphylococcal superantigens induce XCL1 production by human CD4+ and CD8+ T cells. Cytokine 2001; 16:73-78.
28. Nagai S, Hashimoto S, Yamashita T, Toyoda N, Satoh T, Suzuki T, Matsushima K. Comprehensive gene expression profile of human activated T(h)1-and T(h)2-polarized cells. Int Immunol 2001; 13:367-376.
29. Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA, Fine S, Epstein LG, Dairaghi D, Schall TJ, Gendelman HE, Dewhurst S, Sharer LR, Gelbard HA. Neuronal CX3CL1 expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol 2000; 164:1333-1339.
30. Muller K, Bischof S, Sommer F, Lohoff M, Solbach W, Laskay T. Differential production of macrophage inflammatory protein 1gamma (MIP-1gamma), XCL1, and MIP-2 by CD4(+) Th subsets polarized in vitro and in vivo. Infect Immun 2003; 71:6178-6183.
31. Mancardi S, Vecile E, Dusetti N, Calvo E, Stanta G, Burrone OR, Dobrina A. Evidence of CXC, CC and C chemokine production by lymphatic endothelial cells. Immunology 2003; 108:523-530.
32. Bierer BE, Nishimura Y, Burakoff SJ, Smith BR. Phenotypic and functional characterization of human cytolytic T cells lacking expression of CD5. J Clin Invest 1988; 81:1390-1397.
33. Indraccolo S, Mion M, Zamarchi R, Coppola V, Calderazzo F, Amadori A, Chieco-Bianchi L. A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Clin Immunol Immunopathol 1995; 77:253-261.
34. Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major XCL1 (XCL1) source in peripheral blood lymphocytes. J Immunol 2003; 171:4528-4538.
35. Bierer BE, Burakoff SJ, Smith BR. A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood 1989; 73:1359-1366.
36. Yoshida T, Ishikawa I, Ono Y, Imai T, Suzuki R, Yoshie O. An activation-responsive element in single C motif-1/XCL1 promoter is a site of constitutive and inducible DNA-protein interactions involving nuclear factor of activated T cell. J Immunol 1999; 163:3295-3303.
37. Olive D, Cerdan C. CD28 co-stimulation results in down-regulation of XCL1 expression in human CD4(+) but not CD8(+) T cells via an IL-2-dependent mechanism. Eur J Immunol 1999; 29:2443-2453.
38. Maghazachi AA. Intracellular signalling pathways induced by chemokines in natural killer cells. Cell Signal 1999; 11:385-390.
39. Maghazachi AA, Skalhegg BS, Rolstad B, Al-Aoukaty A. Interferon-inducible protein-10 and XCL1 induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxinsensitive and -insensitive heterotrimeric G-proteins. FASEB J 1997; 11:765-774.
40. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O. Identification of single C motif-1/XCL1 receptor XCR1. J Biol Chem 1998; 273:16551-16554.
41. Kurt RA, Bauck M, Harma S, McCulloch K, Baher A, Urba WJ. Role of C chemokine XCL1 in mediating recruitment of antigen-specific CD62L(lo) cells in vitro and in vivo. Cell Immunol 200; 209:83-88.
42. Huang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to XCL1. Biochem Biophys Res Commun 2001; 281:378-382.
43. Cairns CM, Gordon JR, Li F, Baca-Estrada ME, Moyana T, Xiang J. XCL1 expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J Immunol 2001; 167:57-65.
44. Boyaka PN, McGhee JR. Cytokines as adjuvants for the induction of mucosal immunity. Adv Drug Deliv Rev 2001; 51:71-79.
45. Lillard JW Jr, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR. XCL1 acts as an innate mucosal adjuvant. J Immunol 1999; 162:1959-1965.
46. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-242.
47. Wang JD, Nonomura N, Takahara S, Li BS, Azuma H, Ichimaru N, Kokado Y, Matsumiya K, Mild T, Suzuki S, Okuyama A. XCL1: a key regulator of lymphocyte trafficking during acute graft rejection. Immunology 1998; 95:56-61.
48. Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, Woolf N, Campbell IL, Sarvetnick N. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162:2511-2520.
49. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemoldne macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30:1410-1415.
50. Natori Y, Ou ZL, Yamamoto-Shuda Y. Expression of XCL1 mRNA in experimental crescentic glomerulonephritis. Clin Exp Immunol 1998; 113:265-268.
51. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczek RA. MIP-1alpha, MIP-1beta, RANTES, and ATAC/XCL1 function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A 2002; 99:6181-6186.
52. Glassock RJ, Cohen AH. The primary glomerulopathies. Dis Mon 1996; 42:329-383.
53. Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998; 31:1065-1084.
54. Ou ZL, Hotta O, Natori Y, Sugai H, Taguma Y. Enhanced expression of C chemokine XCL1 in IgA nephropathy. Nephron 2002; 91:262-269.
55. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003; 15:15-21.
56. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:715-721.
57. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998; 41:2108-2116.
58. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, Ponath P, Pope RM, Koch AE. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001; 44:2750-2760.
59. Wang CR, Liu MF. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 2003; 132:371-378.
60. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, Reich K, Benoehr P, Koziolek M, Muller GA. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/XCL1 and its functional role in rheumatoid arthritis. Arthritis Rheum 2003; 48:1858-1872.
61. Wang CR, Liu MF, Huang YH, Chen HC. Upregulation of XCR1 expression in rheumatoid joints. Rheumatology 2004; 43:569-573.
62. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol 1998; 19:513-521.
63. Boros DL. T helper cell populations, cytokine dynamics, and pathology of the schistosome egg granuloma. Microbes Infect 1999; 1:511-516.
64. Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW. Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol 2001; 158:1503-1515.
65. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998; 187:601-608.
66. Lo D, Feng L, Li L, Carson MJ, Crowley M, Pauza M, Nguyen A, Reilly CR. Integrating innate and adaptive immunity in the whole animal. Immunol Rev 1999; 169:225-239.
67. Chiu BC, Freeman CM, Stolberg VR, Komuniecki E, Lincoln PM, Kunkel SL, Chensue SW. Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation. Am J Respir Cell Mol Biol 2003; 29:106-116.
68. Petrek M, Kolek V, Szotkowska J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J 2002; 20:1206-1212.
69. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-1234.
70. Keane MP, Standiford TJ, Stricter RM. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. Eur Respir J 1997; 10:1199-1202.
71. Hashimoto S, Nakayama T, Gon Y, Hata N, Koura T, Maruoka S, Matsumoto K, Hayashi S, Abe Y, Horie T. Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1alpha (MIP-1alpha) levels with disease activity and clinical course of sarcoidosis. Clin Exp Immunol 1998; 111:604-610.
72. Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000; 12:71-76.
73. Bocker U, Damiao A, Holt L, Han DS, Jobin C, Panja A, Mayer L, Sartor RB. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology 1998; 115:1426-1438.
74. Klebl FH, Olsen JE, Jain S, Doe WF. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J Pathol 2001; 195:609-615.
75. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, Wrede A, Hummel KM, Gunawan B, Radzun HJ. Expression of the T-cell chemoattractant chemokine XCL1 in Crohn's disease. Am J Pathol 2001; 159:1751-1761.
76. Burgio VL, Fais S, Boirivant M, Perrone A, Pallone F. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology 1995; 109:1029-1038.
77. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2:1090-1095.
78. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human XCL1 with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101:1718-1726.
79. Cerdan C, Serfling E, Olive D. The C-class chemokine, XCL1, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood 2000; 96:420-428.
80. Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002; 217:12-22.
81. Huang H, Xiang J. Synergistic effect of XCL1 and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int J Cancer 2004; 109:817-825.
82. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of CX3CL1 receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-530.
83. Harrison JK, Fong AM, Swain PA, Chen S, Yu YR, Salafranca MN, Greenleaf WB, Imai T, Patel DD. Mutational analysis of the CX3CL1 chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. J Biol Chem 2001; 276:21632-21641.
84. Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of CX3CL1 in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000; 275:34183-34189.
85. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. CX3CL1 and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188:1413-1419.
86. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, Vassileva G, Lira SA. Generation and analysis of mice lacking the chemokine CX3CL1. Mol Cell Biol 2001; 21:3159-3165.
87. Hoover DM, Mizoue LS, Handel TM, Lubkowski J. The crystal structure of the chemokine domain of CX3CL1 shows a novel quaternary arrangement. J Biol Chem 2000; 275:23187-23193.
88. Nomiyama H, Imai T, Kusuda J, Miura R, Callen DF, Yoshie O. Human chemokines CX3CL1 (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13. Cytogenet Cell Genet 1998; 81:10-11.
89. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. CX3CL1 (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107:1173-1181.
90. Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K, Satoh K. Interferon-gamma stimulates CX3CL1 expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol 2001; 25:233-238.
91. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon O, Zerwes HG, Feng L. NF-kappaB-dependent CX3CL1 induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000; 67:577-584.
92. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of CX3CL1 (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 2002; 37:314-327.
93. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/CX3CL1 expression in endothelial cells. J Atheroscler Thromb 2004; 11:15-21.
94. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of CX3CL1 (CX3CL1). J Biol Chem 2001; 276:37993-38001.
95. Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of CX3CL1. J Biol Chem 2001; 276:44622-44626.
96. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F, Greaves DR. The transmembrane form of the CX3CL1 chemokine CX3CL1 is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001; 158:855-866.
97. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP, Reinecker HC. CX3CL1 is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000; 164:3368-3376.
98. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. CX3CL1 is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002; 168:604-612.
99. Wong BW, Wong D, McManus BM. Characterization of CX3CL1 (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002; 11:332-338.
100. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, Saraf MA, Schall T, Blauvelt A, Rosen SD, Hwang ST. CX3CL1, a CX3C chemokine, is expressed by dendritic cells and is upregulated upon dendritic cell maturation. Eur J Immunol 1999; 29:2551-2559.
101. Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K, Inaba K, Imamura S, Honjo T. CX3CL1 and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur J Immunol 1999; 29:1925-1932.
102. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L. Role for neuronally derived CX3CL1 in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998; 95:10896-10901.
103. Greaves DR, Hakkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, CX3CL1, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21:923-929.
104. Pereira CF, Middel J, Jansen G, Verhoef J, Nottet HS. Enhanced expression of CX3CL1 in HIV-1 associated dementia. J Neuroimmunol 2001; 115:168-175.
105. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, Balian A, Richard Y, Galanaud P, Emilie D. CX3CL1 receptor expression by T lymphocyte subpopulations and in vivo production of CX3CL1 in human. Eur J Immunol 2000; 30:87-97.
106. Cotter R, Williams C, Ryan L, Erichsen D, Lopez A, Peng H, Zheng J. CX3CL1 (CX3CL1) and brain inflammation: implications for HIV-1-associated dementia. J Neurovirol 2002; 8:585-598.
107. Cambien B, Pomeranz M, Schmid-Antomarchi H, Millet MA, Breittmayer V, Rossi B, Schmid-Alliana A. Signal transduction pathways involved in soluble CX3CL1-induced monocytic cell adhesion. Blood 2001; 97:2031-2037.
108. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 1997; 275:394-397.
109. Lopez-Ilasaca M. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 1998; 56:269-277.
110. Kansra V, Groves C, Gutierrez-Ramos JC, Polakiewicz RD. Phosphatidylinositol 3-kinase-dependent extracellular calcium influx is essential for CX(3)CR1-mediated activation of the mitogen-activated protein kinase cascade. J Biol Chem 2001; 276:31831-31838.
111. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
112. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-257.
113. Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarization of the immune response. Trends Immunol 2001; 22:502-509.
114. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. CX3CL1 in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24:34-40.
115. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18:593-620.
116. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2:95-101.
117. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
118. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10:581-587.
119. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today 1999; 20:177-180.
120. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. Dual functions of CX3CL1/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168:6173-6180.
121. Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today 1996; 17:424-428.
122. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001; 69:11-20.
123. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, Gabuzda D. CX3CL1 preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197:1701-1707.
124. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67:1033-1036.
125. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-314.
126. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-66.
127. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-3561.
128. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002; 100:3853-3860.
129. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993; 361:79-82.
130. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of CX3CL1-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 1999; 274:10053-10058.
131. Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N, Umehara H. CX3C-chemokine, CX3CL1-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000; 164:4313-4320.
132. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. CX3CL1 and vascular injury. Trends Immunol 2001; 22:602-607.
133. Umehara H, Goda S, Imai T, Nagano Y, Minami Y, Tanaka Y, Okazaki T, Bloom ET, Domae N. CX3CL1, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol 2001; 79:298-302.
134. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine CX3CL1 inhibits Fas-mediated cell death of brain microglia. J Immunol 2000; 165:397-403.
135. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of CX3CL1 in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 1999; 163:1628-1635.
136. Zujovic V, Benavides J, Vige X, Carter C, Taupin V. CX3CL1 modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 2000; 29:305-315.
137. Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N, Umehara H. CX3CL1-mediated endothelial cell injury by NK cells. J Immunol 2000; 164:4055-4062.
138. Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum 2000; 43:1204-1217.
139. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933-944.
140. Yoneda O, Imai T, Mshimura M, Miyaji M, Mimori T, Okazaki T, Domae N, Fujimoto H, Minami Y, Kono T, Bloom ET, Umehara H. Membrane-bound form of CX3CL1 induces IFN-gamma production by NK cells. Eur J Immunol 2003; 33:53-58.
141. Shiraishi K, Fukuda S, Mon T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y, Arakawa H. Identification of CX3CL1, a CX3C-type chemokine, as a direct target of p53. Cancer Res 2000; 60:3722-3726.
142. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14:377-386.
143. Alexander RW. Cytokine receptor CX3CR-1 and CX3CL1: new factors in the atherosclerosis drama? Circ Res 2001; 89:376-377.
144. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89:401-407.
145. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100:20-28.
146. Greaves DR, Channon KM. Inflammation and immune responses in atherosclerosis. Trends Immunol 2002; 23:535-541.
147. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for CX3CL1 in atherogenesis. J Clin Invest 2003; 111:333-340.
148. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107:1009-1016.
149. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287:2274-2277.
150. Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C. Polymorphism in the CX3CL1 receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97:1925-1928.
151. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117.
152. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144:275-285.
153. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D, Humbert M. CX(3)C chemokine CX3CL1 in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:1419-1425.
154. Williams TJ. Stalking the chemokine. Am J Respir Crit Care Med 2002; 165:1350-1351.
155. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM. A role for CX3CL1 and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000; 165:6067-6072.
156. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF. Targeted deletion of CX(3)CR1 reveals a role for CX3CL1 in cardiac allograft rejection. J Clin Invest 2001; 108:679-688.
157. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P, Levy Y, Emilie D. Deregulation of the expression of the CX3CL1/CX3CL1 receptor complex in HIV-1-infected patients. Blood 2001; 98:1678-1686.
158. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadiere C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000; 290:2031.
159. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A 2000; 97:8075-8080.
160. Deshmukh M, Vasilakos J, Deckwerth TL, Lampe PA, Shivers BD, Johnson EM Jr. Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases. J Cell Biol 1996; 135:1341-1354.
161. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189:865-870.
162. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L. Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 2001; 113:193-201.
163. Garaci E, Caroleo MC, Aloe L, Aquaro S, Piacentini M, Costa N, Amendola A, Micera A, Calio R, Perno CF, Levi-Montalcini R. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A 1999; 96:14013-14018.
164. Chao CC, Hu S, Sheng WS, Tsang M, Peterson PK. Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures. Clin Immunol Immunopathol 1995; 77:358-365.
165. Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999; 19:1708-1716.
166. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, Hayashida K, Hasegawa J, Yoshie O, Miyasaka N. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:2878-2883.
167. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. CX3CL1: a novel angiogenic chemokine in rheumatoid arthritis. AmJ Pathol 2001; 159:1521-1530.
168. Blaschke S, Koziolek M, Schwarz A, Benohr P, Middel P, Schwarz G, Hummel KM, Muller GA. Proinflammatory role of CX3CL1 (CX3CL1) in rheumatoid arthritis. J Rheumatol 2003; 30:1918-1927.
169. Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S. Expression of CX3CL1 and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J Allergy Clin Immunol 2004; 113:940-948.
170. Raychaudhuri SP, Jiang WY, Farber EM. Cellular localization of CX3CL1 at sites of inflammation: antigen-presenting cells in psoriasis express high levels of CX3CL1. Br J Dermatol 2001; 144:1105-1113.
171. Rimaniol AC, Till SJ, Garcia G, Capel F, Godot V, Balabanian K, Durand-Gasselin I, Varga EM, Simonneau G, Emilie D, Durham SR, Humbert M. The CX3C chemokine CX3CL1 in allergic asthma and rhinitis. J Allergy Clin Immunol 2003; 112:1139-1146.
172. Efsen E, Grappone C, DeFranco RM, Milani S, Romanelli RG, Bonacchi A, Caligiuri A, Failli P, Annunziato F, Pagliai G, Pinzani M, Laffi G, Gentilini P, Marra F. Up-regulated expression of CX3CL1 and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002; 37:39-47.
173. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-CX3CL1 expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004; 64:4693-4698.
174. Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, Thompson DA, Siani MA, Yamamoto T, Harrison JK, Feng L. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998; 188:193-198.
175. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB. Prevention of crescentic glomerulonephritis by immunoneutralization of the CX3CL1 receptor CX3CR1 rapid communication. Kidney Int 1999; 56:612-620.
176. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Shimizu M, Kobayashi K, Takasawa K, Kida H, Takeda S, Matsushima K, Yokoyama H. Upregulation of CX3CL1 in human crescentic glomerulonephritis. Nephron 2001; 87:314-320.
177. Ito Y, Kawachi H, Morioka Y, Nakatsue T, Koike H, Ikezumi Y, Oyanagi A, Natori Y, Nakamura T, Gejyo F, Shimizu F. CX3CL1 expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 2002; 61:2044-2057.
178. Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the CX3CL1 receptor (CX3CR1) in human kidney diseases. Kidney Int 2002; 62:488-495.
179. Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO. CX3CL1 expression in human renal inflammation. J Pathol 2002; 196:85-90.
180. Hall CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr 1999; 135:2-7.
181. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2:732-738.